Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The FDA approved a new Pfizer drug for hair loss in teens.

Baricitinib is a safe and effective treatment for severe alopecia areata.

This report presented a case of a patient with basal cell carcinoma and systemic lupus erythematosus who was treated successfully with sonidegib, showing positive outcomes without worsening lupus activity, despite lacking documented clinical use of sonidegib in such patients.

This study found that chronic high dosages of 2-(difluoromethyl)-dl-ornithine caused various toxicities in rats and dogs, with some effects potentially minimized at lower dosages.

This case report describes severe hypothyroidism exacerbated by nephrotic syndrome in a 62-year-old woman, with a diagnosis of membranous nephropathy linked to significant proteinuria.

This study found that methylprednisolone pulse therapy may be an effective treatment option for patients with severe multifocal alopecia areata, particularly those experiencing their first episode.

Abatacept may help some people with alopecia areata regrow hair.

This correspondence about the treatment of chronic alopecia areata with tildrakizumab reports no clinical results; the authors present an open-label pilot study setup.

This report describes a case of universal alopecia in a patient with rheumatoid arthritis while using adalimumab and leflunomide, suggesting a potential link between these drugs and alopecia areata.

In this study, baricitinib improved the resolution of arthritis or rash in patients with systemic lupus erythematosus, but outcomes for skin involvement like alopecia were not reported.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This article examines the potential of using oral minoxidil as an adjuvant treatment for patients with severe alopecia areata who do not respond to increased doses of Janus kinase inhibitors, but provides no new clinical results.

This communication discusses previous reports of deadly hematopoietic depression associated with the topical use of demecolcine for skin cancers, highlighting potential hazards relative to colchicine ointment in psoriasis.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

This study found that trilostane was effective in resolving symptoms such as polyuria and polydipsia in many dogs with pituitary-dependent hyperadrenocorticism, with significant hormone level reductions observed.

In this case study, a 69-year-old woman with severe hypercortisolism developed acute adrenal insufficiency after starting ketoconazole treatment, highlighting the need for cautious dosing and close monitoring of adrenal function, particularly in patients with prior glucocorticoid exposure.

This case report describes the development of halo naevi, vitiligo, and diffuse alopecia areata in a 33-year-old woman undergoing tocilizumab therapy, suggesting a link between these conditions and cellular and humoral immune factors.

In this case study, intravenous cyclophosphamide pulse therapy effectively improved symptoms of steroid-resistant lupus cystitis and peritonitis, allowing for a reduction in steroid dosage.

In this study, baricitinib treatment for severe alopecia areata was well tolerated, with minor metabolic changes and PLR emerging as a sensitive marker of treatment response.

In this case report, tofacitinib led to significant improvement in arthritis and partial improvement in alopecia for a female patient with systemic lupus erythematosus, with no observed adverse effects.

This case report documents the development of vitiligo-like lesions in a patient with autoimmune thyroiditis following the use of topical squaric acid dibutylester for alopecia.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

This study found that in pregnant rats, the suppression of ACTH responses to IL-1β is linked to the action of endogenous opioids and AP, with AP potentially inducing opioid inhibition through increased pENK-A expression.

In this study, a case of a patient with dermatomyositis and alopecia universalis showed successful treatment with tofacitinib, suggesting potential responsiveness to janus kinase inhibitors.

This case report describes the development of central serous retinopathy after prescribing a low dose of prednisolone for androgenic alopecia, which resolved after gradual steroid withdrawal.

This article discusses the importance of raising awareness about specific adverse drug reactions, methods of prevention, and the significance of reporting them to the FDA's MedWatch program, but reports no new clinical results.

This article discusses arsenic trioxide as a treatment for refractory or relapsed acute promyelocytic leukemia, noting its effectiveness and manageable side effects.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.